Back to Results

Phase 1 study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK-3B) inhibitor, as a single agent or with Irinotecan in pediatric patients with refractory malignancies

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Child to Adult

Phase

I - Research Studies that focus on the safety of a drug. The goal is to determine the drug's most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These studies usually involve a small number of participants.

Type of Study

Treatment

Location

Childrens Hospital Colorado

Principal Investigator
Margaret Macy

Margaret Macy

Study ID

Protocol Number: 20-1445

More information available at ClinicalTrials.gov: NCT04239092

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers